SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral,...

Annals of the Rheumatic Diseases 2015 / 06 Vol. 74; Iss. Suppl 2

SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure

Smith, P.F., Krishnarajah, J., Nunn, P.A., Hill, R.J., Karr, D., Tam, D., Masjedizadeh, M., Gourlay, S.G.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
74
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2015-eular.4289
Date:
June, 2015
File:
PDF, 82 KB
english, 2015
Conversion to is in progress
Conversion to is failed